Clazakizumab (Anti-Il6 Monoclonal) to Reduce Donor Specific HLA Antibodies (DSA) and Improve Outcomes in Post- Kidney Transplant Patients with Chronic Active Antibody Mediated Rejection (NCT03380377)
AMERICAN JOURNAL OF TRANSPLANTATION（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要